DC-106

DC-106 (also known as G-103) is an orally bioavailable small molecule being developed by Gibson Oncology for the treatment of hematologic and solid tumors. It belongs to the indenoisoquinoline class of compounds, which are non-camptothecin inhibitors of DNA topoisomerase 1 (Top1). Unlike camptothecin derivatives, indenoisoquinolines like DC-106 form stable cleavage complexes with DNA and Top1, are chemically stable, and are not substrates for common efflux transporters such as ABCG2, which often contribute to drug resistance. DC-106 is designed to induce lethal DNA double-strand breaks in cancer cells by preventing the religation of DNA during the Top1 catalytic cycle. The drug is currently in the early stages of development for a broad range of oncological indications.